Last reviewed · How we verify
Corticosteroid: Triamcinolone
Corticosteroid: Triamcinolone is a Corticosteroid Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 2 development for Nephrotic syndrome, Severe asthma, Severe allergies.
Glucocorticoid receptor agonist
Triamcinolone is a glucocorticoid receptor agonist, classified as a small molecule in the drug class of agonists. It has been studied as a treatment for conditions such as Carpal Tunnel Syndrome, Knee Osteoarthritis, and Degenerative Joint Disease through injections of Triamcinolone Acetonide.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies. -
Big-pharma sponsor
+3.0pp
Bristol-Myers Squibb is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Corticosteroid: Triamcinolone |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Triamcinolone acts as a synthetic glucocorticoid receptor agonist, which leads to anti-inflammatory and immunosuppressive effects.
Approved indications
- Nephrotic syndrome
- Severe asthma
- Severe allergies
Common side effects
- Cushing's syndrome
- Adrenal insufficiency
- Glaucoma
Key clinical trials
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants (PHASE2)
- Corticosteroid Meniscectomy Randomized Trial (PHASE4)
- Microneedling for Burn Hypertrophic Scars (NA)
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (PHASE2)
- A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corticosteroid: Triamcinolone CI brief — competitive landscape report
- Corticosteroid: Triamcinolone updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Corticosteroid: Triamcinolone
What is Corticosteroid: Triamcinolone?
How does Corticosteroid: Triamcinolone work?
What is Corticosteroid: Triamcinolone used for?
Who makes Corticosteroid: Triamcinolone?
What drug class is Corticosteroid: Triamcinolone in?
What development phase is Corticosteroid: Triamcinolone in?
What are the side effects of Corticosteroid: Triamcinolone?
What does Corticosteroid: Triamcinolone target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Nephrotic syndrome
- Indication: Drugs for Severe asthma
- Indication: Drugs for Severe allergies
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing